Micronase

Pronunciation: GLYE-bure-ide
Generic Name: Glyburide
Brand Name: DiaBeta

Micronase is used for:

Treating type 2 diabetes. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines.

Micronase is a sulfonylurea antidiabetic medicine. It works by causing the pancreas to release insulin, which helps to lower blood sugar.

Do NOT use Micronase if:

• you are allergic to any ingredient in Micronase


• you have type 1 diabetes or certain severe problems associated with diabetes (eg, diabetic ketoacidosis, diabetic coma)


• you have moderate to severe burns or very high blood acid levels (acidosis)


• you are pregnant and are within 2 weeks of the expected delivery date


• you are taking bosentan

Contact your doctor or health care provider right away if any of these apply to you.

Before using Micronase:

Some medical conditions may interact with Micronase. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have had a severe allergic reaction (eg, a severe rash, hives, itching, breathing difficulties, dizziness) to any other sulfonamide medicine, such as acetazolamide, celecoxib, certain diuretics (eg, hydrochlorothiazide), glipizide, probenecid, sulfamethoxazole, valdecoxib, or zonisamide


• if you have a history of liver, kidney, thyroid, or heart problems


• if you have stomach or bowel problems (eg, stomach or bowel blockage, stomach paralysis), drink alcohol, or have had poor nutrition


• if you have a certain nerve problem (autonomic neuropathy), very poor health, a high fever, a severe infection, severe diarrhea, or high blood acid levels, or have had a severe injury


• if you have a history of certain hormonal problems (eg, adrenal or pituitary problems, syndrome of inappropriate secretion of antidiuretic hormone [SIADH]), low blood sodium levels, anemia, or glucose-6-phosphate dehydrogenase (G6PD) deficiency


• if you will be having surgery

Some MEDICINES MAY INTERACT with Micronase. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Bosentan because liver problems may occur and the effectiveness of both medicines may be decreased


• Beta-blockers (eg, propranolol) because the risk of low blood sugar may be increased. They may also hide certain signs of low blood sugar and make it more difficult to notice


• Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), anticoagulants (eg, warfarin), azole antifungals (eg, ketoconazole, miconazole), chloramphenicol, clarithromycin, clofibrate, disopyramide, fenfluramine, fluoxetine, insulin, monoamine oxidase inhibitors (MAOIs) (eg, phenelzine), nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), phenylbutazone, probenecid, quinolone antibiotics (eg, ciprofloxacin), salicylates (eg, aspirin), or sulfonamides (eg, sulfamethoxazole) because the risk of low blood sugar may be increased


• Calcium channel blockers (eg, diltiazem), corticosteroids (eg, prednisone), decongestants (eg, pseudoephedrine), diazoxide, diuretics (eg, furosemide, hydrochlorothiazide), estrogens, hormonal contraceptives (eg, birth control pills), hydantoins (eg, phenytoin), isoniazid, niacin, phenothiazines (eg, promethazine), rifamycins (eg, rifampin), sympathomimetics (eg, albuterol, epinephrine, terbutaline), or thyroid supplements (eg, levothyroxine) because they may decrease Micronase's effectiveness, resulting in high blood sugar


• Gemfibrozil because blood sugar may be increased or decreased


• Cyclosporine because the risk of its side effects may be increased by Micronase

This may not be a complete list of all interactions that may occur. Ask your health care provider if Micronase may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Micronase:

Use Micronase as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Micronase by mouth with food as directed by your doctor.


• If you are taking 1 dose daily, take Micronase with breakfast or the first main meal of the day unless your doctor tells you otherwise.


• High amounts of dietary fiber may decrease Micronase's effectiveness, resulting in high blood sugar. If you have questions about fiber in your diet while you are taking Micronase, talk with your doctor.


• Micronase works best if it is taken at the same time each day.


• Continue to take Micronase even if you feel well. Do not miss any doses.


• If you miss a dose of Micronase, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Micronase.

Important safety information:

• Micronase may cause drowsiness, dizziness, blurred vision, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Micronase with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink large amounts of alcohol while you use Micronase. Alcohol may increase the risk of Micronase's side effects. Also, alcohol may rarely interact with Micronase and cause a serious reaction with symptoms such as flushing, nausea, vomiting, dizziness, or stomach pain. Talk with your doctor or health care provider before you drink alcohol while you use Micronase.


• Carry an ID card at all times that says you have diabetes. Check your blood sugar levels as directed by your doctor. If they are often higher or lower than they should be and you take Micronase exactly as prescribed, tell your doctor.


• Proper diet, regular exercise, and regular blood sugar testing are important for best results with Micronase. Follow the diet and exercise program given to you by your health care provider.


• It may be harder to control your blood sugar during times of stress such as fever, infection, injury, or surgery. Talk with your doctor about how to control your blood sugar if any of these occur. Do not change the dose of your medicine without checking with your doctor.


• Micronase may cause low blood sugar levels. Low blood sugar may make you anxious, sweaty, weak, dizzy, drowsy, or faint. It may also make your heart beat faster; make your vision change; give you a headache, chills, or tremors; or make you more hungry. It is a good idea to carry a reliable source of glucose (eg, tablets or gel) to treat low blood sugar. If this is not available, you should eat or drink a quick source of sugar like table sugar, honey, candy, orange juice, or non-diet soda. This will raise your blood sugar level quickly. Tell your doctor right away if this happens. To prevent low blood sugar, eat meals at the same time each day and do not skip meals.


• Risk of low blood sugar may be increased by severe or prolonged exercise, drinking alcohol, or skipping meals.


• Micronase is a sulfonylurea. It may increase the risk of death from heart disease. Talk with your doctor about the benefits and risks of this or other therapies to treat your condition.


• Micronase may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Micronase. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Do not change from this type of glyburide (nonmicronized) to the micronized type without checking with your doctor. Their effectiveness may not be the same.


• Micronase should not be used by itself to treat type 1 diabetes. If you have questions about using Micronase to treat type 1 diabetes, talk with your doctor.


• Tell your doctor or dentist that you take Micronase before you receive any medical or dental care, emergency care, or surgery.


• Lab tests, including fasting blood glucose and hemoglobin A_1c, may be performed while you use Micronase. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Micronase with caution in the ELDERLY; they may be more sensitive to its effects, especially low blood sugar levels.


• Micronase should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Micronase while you are pregnant. If you take Micronase during pregnancy, do not take it within 2 weeks of the expected delivery date without first checking with your doctor. It is not known if Micronase is found in breast milk. Do not breast-feed while taking Micronase.

When used for long periods of time, Micronase may not work as well. If your blood sugar has been under control and then becomes hard to manage, contact your doctor. Do not change the dose of your medicine without checking with your doctor.

Possible side effects of Micronase:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Feeling of stomach fullness; heartburn; nausea.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing, joint or muscle pain, tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); blisters on the skin; confusion; fainting; fever, chills, or persistent sore throat; irregular heartbeat; low blood sugar symptoms (eg, anxiety, dizziness, drowsiness, fast heartbeat, headache, lightheadedness, tremors, unusual sweating, weakness); severe or persistent blurred vision or other vision problems; symptoms of liver problems (eg, dark urine, loss of appetite, pale stools, stomach pain, yellowing of the eyes or skin); unusual bruising or bleeding; unusual tiredness or weakness.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Micronase side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; confusion; fainting; fast heartbeat; lethargy; lightheadedness; seizures; severe dizziness or drowsiness; tremor; unusual sweating.

Proper storage of Micronase:

Store Micronase at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Micronase out of the reach of children and away from pets.

General information:

• If you have any questions about Micronase, please talk with your doctor, pharmacist, or other health care provider.


• Micronase is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Micronase. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Micronase resources

• Micronase Side Effects (in more detail)
• Micronase Dosage
• Micronase Use in Pregnancy & Breastfeeding
• Drug Images
• Micronase Drug Interactions
• Micronase Support Group
• 0 Reviews for Micronase - Add your own review/rating

• Micronase Prescribing Information (FDA)


• Micronase Advanced Consumer (Micromedex) - Includes Dosage Information


• Micronase Concise Consumer Information (Cerner Multum)


• DiaBeta Prescribing Information (FDA)


• Glyburide Monograph (AHFS DI)


• Glyburide Professional Patient Advice (Wolters Kluwer)

Compare Micronase with other medications

• Diabetes, Type 2

RAN-Tamsulosin

RAN-Tamsulosin may be available in the countries listed below.

Ingredient matches for RAN-Tamsulosin

Tamsulosin

Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of RAN-Tamsulosin in the following countries:

• Canada

International Drug Name Search

Malotilate

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0059937-28-9

Chemical Formula

C12-H16-O4-S2

Molecular Weight

288

Therapeutic Category

Hepatoprotective agent

Chemical Name

Propanedioic acid, 1,3-dithiol-2-ylidene-, bis(1-methylethyl) ester

Foreign Names

• Malotilatum (Latin)
• Malotilat (German)
• Malotilate (French)
• Malotilato (Spanish)

Generic Names

• Malotilate (OS: USAN, JAN)
• NKK 105 (IS)

Brand Name

• Kantec
  Daiichi Sankyo, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Flufenazina

Flufenazina may be available in the countries listed below.

Ingredient matches for Flufenazina

Fluphenazine

Flufenazina (DCIT) is known as Fluphenazine in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Risperidona Decrox

Risperidona Decrox may be available in the countries listed below.

Ingredient matches for Risperidona Decrox

Risperidone

Risperidone is reported as an ingredient of Risperidona Decrox in the following countries:

• Spain

International Drug Name Search

Mirapex ER Extended-Release Tablets

Pronunciation: PRAM-i-PEX-ole
Generic Name: Pramipexole
Brand Name: Mirapex ER

Mirapex ER Extended-Release Tablets are used for:

Treating the signs and symptoms of early Parkinson disease. It may also be used for other conditions as determined by your doctor.

Mirapex ER Extended-Release Tablets are a dopamine agonist. Exactly how Mirapex ER Extended-Release Tablets works is unknown. It may increase the action of certain chemical receptors in the brain.

Do NOT use Mirapex ER Extended-Release Tablets if:

• you are allergic to any ingredient in Mirapex ER Extended-Release Tablets


• you have severe kidney problems or are on dialysis


• you are taking another medicine that has pramipexole in it

Contact your doctor or health care provider right away if any of these apply to you.

Before using Mirapex ER Extended-Release Tablets:

Some medical conditions may interact with Mirapex ER Extended-Release Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have kidney problems, low blood pressure, lightheadedness when you sit or stand up, or daytime sleepiness


• if you drink alcohol or have a history of compulsive behavior (eg, eating, gambling, shopping)


• if you have trouble controlling your muscles

Some MEDICINES MAY INTERACT with Mirapex ER Extended-Release Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Cimetidine because it may increase the risk of Mirapex ER Extended-Release Tablets's side effects


• Butyrophenones (eg, haloperidol), metoclopramide, phenothiazines (eg, chlorpromazine), or thioxanthenes (eg, thiothixene) because they may decrease Mirapex ER Extended-Release Tablets's effectiveness


• Levodopa because the risk of its side effects may be increased by Mirapex ER Extended-Release Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Mirapex ER Extended-Release Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Mirapex ER Extended-Release Tablets:

Use Mirapex ER Extended-Release Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with Mirapex ER Extended-Release Tablets. Talk to your pharmacist if you have questions about this information.


• Take Mirapex ER Extended-Release Tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• Swallow Mirapex ER Extended-Release Tablets whole. Do not break, crush, or chew before swallowing.


• Your dose will be started low and gradually increased to achieve the best results. Do not change your dose sooner than recommended.


• Do not suddenly stop taking Mirapex ER Extended-Release Tablets without checking with your doctor. Severe side effects, including fever, mental or mood changes, and stiff muscles, may occur.


• If you miss a dose of Mirapex ER Extended-Release Tablets, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. If you miss several doses, contact your doctor before you start to take Mirapex ER Extended-Release Tablets again.

Ask your health care provider any questions you may have about how to use Mirapex ER Extended-Release Tablets.

Important safety information:

• Mirapex ER Extended-Release Tablets may cause drowsiness or dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Mirapex ER Extended-Release Tablets with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Do not drink alcohol while you are using Mirapex ER Extended-Release Tablets.


• Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Mirapex ER Extended-Release Tablets; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Mirapex ER Extended-Release Tablets may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.


• Some patients who take Mirapex ER Extended-Release Tablets have reported suddenly falling asleep while performing daily activities (eg, driving, eating, conversing). Many patients reported drowsiness before falling asleep; however, some patients did not experience drowsiness and felt that they were alert immediately before suddenly falling asleep. Use caution when driving, operating machinery, or performing other activities that could be dangerous. Inform your doctor if you experience unusual drowsiness or sleepiness while using Mirapex ER Extended-Release Tablets.


• Some people have experienced new, unusual, or increased urges (eg, gambling, sexual urges) while using Mirapex ER Extended-Release Tablets. Tell your doctor right away if you notice such effects.


• Patients with Parkinson disease may have an increased risk of developing a certain type of skin cancer (melanoma). It is not known if Mirapex ER Extended-Release Tablets also increases the risk of melanoma. You may need to have skin exams while you are using Mirapex ER Extended-Release Tablets. Discuss any questions or concerns with your doctor.


• Lab tests, including blood pressure or skin checks, may be performed while you use Mirapex ER Extended-Release Tablets. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Mirapex ER Extended-Release Tablets with caution in the ELDERLY; they may be more sensitive to its effects, especially hallucinations.


• Mirapex ER Extended-Release Tablets should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Mirapex ER Extended-Release Tablets while you are pregnant. It is not known if Mirapex ER Extended-Release Tablets are found in breast milk. Do not breast-feed while taking Mirapex ER Extended-Release Tablets.

Possible side effects of Mirapex ER Extended-Release Tablets:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; cough; dizziness; drowsiness; dry mouth; muscle spasms; nausea; stomach pain or upset; tiredness; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); abnormal thinking; balance problems; change in behavior, mood, or emotions; chest pain; confusion; decreased sexual ability; difficulty walking; fainting; hallucinations; increased urination; memory loss; muscle pain, tenderness, or weakness; new or unusual skin growths; severe or persistent drowsiness or sleepiness; shortness of breath; sudden irresistible urge to sleep or suddenly falling asleep at unusual times; swelling of the arms or legs; trouble swallowing; unusual or intense urges (eg, gambling, sexual urges); unusual twitching or muscle movements; vision changes; vivid dreams or daydreams.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Mirapex ER side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include agitation; chest pain; confusion; decrease in blood pressure; difficulty moving; drowsiness; nausea; sedation; vomiting.

Proper storage of Mirapex ER Extended-Release Tablets:

Store Mirapex ER Extended-Release Tablets at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Mirapex ER Extended-Release Tablets out of the reach of children and away from pets.

General information:

• If you have any questions about Mirapex ER Extended-Release Tablets, please talk with your doctor, pharmacist, or other health care provider.


• Mirapex ER Extended-Release Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Mirapex ER Extended-Release Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Mirapex ER resources

• Mirapex ER Side Effects (in more detail)
• Mirapex ER Use in Pregnancy & Breastfeeding
• Drug Images
• Mirapex ER Drug Interactions
• 0 Reviews for Mirapex ER - Add your own review/rating

Compare Mirapex ER with other medications

• Parkinson's Disease

Adco-Cefoxitin

Adco-Cefoxitin may be available in the countries listed below.

Ingredient matches for Adco-Cefoxitin

Cefoxitin

Cefoxitin sodium salt (a derivative of Cefoxitin) is reported as an ingredient of Adco-Cefoxitin in the following countries:

• South Africa

International Drug Name Search

Salodan

Salodan may be available in the countries listed below.

Ingredient matches for Salodan

Indometacin

Indometacin is reported as an ingredient of Salodan in the following countries:

• Japan

International Drug Name Search

Risperidona Tosicina

Risperidona Tosicina may be available in the countries listed below.

Ingredient matches for Risperidona Tosicina

Risperidone

Risperidone is reported as an ingredient of Risperidona Tosicina in the following countries:

• Spain

International Drug Name Search

Glucoxidine

Glucoxidine may be available in the countries listed below.

Ingredient matches for Glucoxidine

Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Glucoxidine in the following countries:

• Japan

International Drug Name Search

Isoniazid-Darnitsa

Isoniazid-Darnitsa may be available in the countries listed below.

Ingredient matches for Isoniazid-Darnitsa

Isoniazid

Isoniazid is reported as an ingredient of Isoniazid-Darnitsa in the following countries:

• Georgia

International Drug Name Search

Nepatic

Nepatic may be available in the countries listed below.

Ingredient matches for Nepatic

Gabapentin

Gabapentin is reported as an ingredient of Nepatic in the following countries:

• Indonesia

International Drug Name Search

R Pen

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for R Pen

Benzylpenicillin

Benzylpenicillin potassium (a derivative of Benzylpenicillin) is reported as an ingredient of R Pen in the following countries:

• United States

International Drug Name Search

Paroxetine Mesylate

Pronunciation: par-OX-e-teen MES-i-late
Generic Name: Paroxetine Mesylate
Brand Name: Pexeva

Antidepressants may increase the risk of suicidal thoughts or actions in children, teenagers, and young adults. However, depression and certain other mental problems may also increase the risk of suicide. Talk with the patient's doctor to be sure that the benefits of using Paroxetine Mesylate outweigh the risks.

Families and caregivers must closely watch patients who take Paroxetine Mesylate. It is important to keep in close contact with the patient's doctor. Tell the doctor right away if the patient has symptoms like worsened depression, suicidal thoughts, or changes in behavior. Discuss any questions with the patient's doctor.

Paroxetine Mesylate is used for:

Treating depression, obsessive-compulsive disorder (OCD), panic disorder, or generalized anxiety disorder (GAD). It may also be used for other conditions as determined by your doctor.

Paroxetine Mesylate is a selective serotonin reuptake inhibitor (SSRI). It works by restoring the balance of serotonin, a natural substance in the brain, which helps to improve certain mood problems.

Do NOT use Paroxetine Mesylate if:

• you are allergic to any ingredient in Paroxetine Mesylate


• you are taking or have taken linezolid, methylene blue, a monoamine oxidase inhibitor (MAOI) (eg, phenelzine), selegiline, or St. John's wort within the last 14 days


• you are taking a fenfluramine derivative (eg, dexfenfluramine), nefazodone, pimozide, a serotonin-norepinephrine reuptake inhibitor (SNRI) (eg, venlafaxine), another SSRI (eg, fluoxetine), sibutramine, thioridazine, or tryptophan

Contact your doctor or health care provider right away if any of these apply to you.

Video: Treatment for Depression

Treatments for depression are getting better everyday and there are things you can start doing right away.

Before using Paroxetine Mesylate:

Some medical conditions may interact with Paroxetine Mesylate. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you or a family member has a history of bipolar disorder (manic-depression), other mental or mood problems, suicidal thoughts or attempts, or alcohol or substance abuse


• if you have a history of seizures, heart problems, liver problems, severe kidney problems, stomach or bowel bleeding, narrow-angle glaucoma, diabetes, or metabolism problems


• if you are dehydrated, have low blood sodium levels, or drink alcohol


• if you will be having electroconvulsive therapy (ECT)

Some MEDICINES MAY INTERACT with Paroxetine Mesylate. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Anorexiants (eg, phentermine), cimetidine, fenfluramine derivatives (eg, dexfenfluramine), fentanyl, linezolid, lithium, MAOIs (eg, phenelzine), methylene blue, metoclopramide, nefazodone, selegiline, serotonin 5-HT₁ receptor agonists (eg, sumatriptan), sibutramine, SNRIs (eg, venlafaxine), another SSRI (eg, fluoxetine), St. John's wort, tramadol, trazodone, or tryptophan because severe side effects, such as a reaction that may include fever, rigid muscles, blood pressure changes, mental changes, confusion, irritability, agitation, delirium, or coma, may occur


• Anticoagulants (eg, warfarin), aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen) because the risk of bleeding, including stomach bleeding, may be increased


• Diuretics (eg, furosemide, hydrochlorothiazide) because the risk of low blood sodium levels may be increased


• Antiarrhythmics (eg, flecainide, propafenone, quinidine), astemizole, phenothiazines (eg, chlorpromazine, thioridazine), or terfenadine because severe heart problems, including irregular heartbeat, may occur


• Cyproheptadine, HIV protease inhibitors (eg, ritonavir), phenobarbital, or phenytoin because they may decrease Paroxetine Mesylate's effectiveness


• Aripiprazole, atomoxetine, clozapine, fluoxetine, pimozide, procyclidine, risperidone, theophylline, or tricyclic antidepressants (eg, amitriptyline) because the risk of their side effects may be increased by Paroxetine Mesylate


• Digoxin or tamoxifen because their effectiveness may be decreased by Paroxetine Mesylate

This may not be a complete list of all interactions that may occur. Ask your health care provider if Paroxetine Mesylate may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Paroxetine Mesylate:

Use Paroxetine Mesylate as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Paroxetine Mesylate comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Paroxetine Mesylate refilled.


• Take Paroxetine Mesylate by mouth with or without food.


• Swallow Paroxetine Mesylate whole. Do not crush or chew before swallowing.


• Taking Paroxetine Mesylate at the same time each day will help you remember to take it.


• Continue to take Paroxetine Mesylate even if you feel well. Do not miss any doses.


• Do not suddenly stop taking Paroxetine Mesylate without checking with your doctor. Side effects may occur. They may include mental or mood changes, numbness or tingling of the skin, ringing in the ears, dizziness, confusion, headache, trouble sleeping, or unusual tiredness. You will be closely monitored when you start Paroxetine Mesylate and whenever a change in dose is made.


• If you miss a dose of Paroxetine Mesylate, take it as soon as possible. If it almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Paroxetine Mesylate.

Important safety information:

• Paroxetine Mesylate may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Paroxetine Mesylate with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Paroxetine Mesylate; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.


• Do not drink alcohol while you are taking Paroxetine Mesylate.


• Several weeks may pass before your symptoms get better. Do NOT take more than the recommended dose, change your dose, or use Paroxetine Mesylate for longer than prescribed without checking with your doctor.


• Children, teenagers, and young adults who take Paroxetine Mesylate may be at increased risk of suicidal thoughts or actions. Closely watch all patients who take Paroxetine Mesylate. Contact the doctor at once if new, worsened, or sudden symptoms such as depressed mood; anxious, restless, or irritable behavior; panic attacks; or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.


• If your doctor tells you to stop taking Paroxetine Mesylate, you will need to wait for several weeks before beginning to take certain other medicines (eg, MAOIs, nefazodone). Ask your doctor when you should start to take your new medicines after you have stopped taking Paroxetine Mesylate.


• Paroxetine Mesylate may rarely cause a prolonged, painful erection. This could happen even when you are not having sex. If this is not treated right away, it could lead to permanent sexual problems such as impotence. Contact your doctor right away if this happens.


• Serotonin syndrome is a possibly fatal syndrome that can be caused by Paroxetine Mesylate. Your risk may be greater if you take Paroxetine Mesylate with certain other medicines (eg, "triptans," MAOIs). Symptoms may include agitation; confusion; hallucinations; coma; fever; fast or irregular heartbeat; tremor; excessive sweating; and nausea, vomiting, or diarrhea. Contact your doctor at once if you have any of these symptoms.


• Neuroleptic malignant syndrome (NMS) is a possibly fatal syndrome that can be caused by Paroxetine Mesylate. Your risk may be greater if Paroxetine Mesylate is used with certain other medicines called antipsychotics (eg, aripiprazole, risperidone). Symptoms may be similar to serotonin syndrome and may include fever, rigid muscles, blood pressure changes, and mental changes. Contact your doctor at once if you have any of these symptoms.


• Paroxetine Mesylate may affect fertility in some men. Discuss any questions or concerns with your doctor.


• Use Paroxetine Mesylate with caution in the ELDERLY; they may be more sensitive to its effects, especially low blood sodium levels.


• Caution is advised when using Paroxetine Mesylate in CHILDREN; they may be more sensitive to its effects, especially increased risk of suicidal thoughts or actions.


• Paroxetine Mesylate should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• Paroxetine Mesylate may cause weight changes. CHILDREN and teenagers may need regular weight and growth checks while they take Paroxetine Mesylate.


• PREGNANCY and BREAST-FEEDING: Paroxetine Mesylate may cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Paroxetine Mesylate while you are pregnant. Paroxetine Mesylate is found in breast milk. If you are or will be breast-feeding while you take Paroxetine Mesylate, check with your doctor. Discuss any possible risks to your baby.

Possible side effects of Paroxetine Mesylate:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Anxiety; blurred vision; constipation; decreased sexual desire or ability; diarrhea; dizziness; drowsiness; dry mouth; gas; increased sweating; increased urination; loss of appetite; nausea; nervousness; numbness or tingling of the skin; stomach upset; trouble sleeping; weakness; yawning.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bizarre behavior; black or bloody stools; chest pain; confusion; decreased concentration; decreased coordination; exaggerated reflexes; fainting; fast or irregular heartbeat; fever, chills, or sore throat; hallucinations; memory loss; new or worsening mental or mood changes (eg, agitation, panic attacks, aggressiveness, impulsiveness, irritability, hostility, exaggerated feeling of well-being, restlessness, or inability to sit still); persistent or severe ringing in the ears; persistent, painful erection; red, swollen, blistered, or peeling skin; seizures; severe or persistent anxiety or trouble sleeping; severe or persistent headache or dizziness; significant weight loss; stomach pain; suicidal thoughts or attempts; tremor; unusual bone pain or unexplained swelling, tenderness, or bruising; unusual bruising or bleeding; unusual weakness; vision changes; worsening of depression.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Paroxetine Mesylate side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; confusion; dilated pupils; fainting; fast, slow, or irregular heartbeat; inability to urinate; seizures; severe muscle pain; severe or persistent dizziness, drowsiness, nausea, or vomiting; tremor; yellowing of the eyes or skin.

Proper storage of Paroxetine Mesylate:

Store Paroxetine Mesylate at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Paroxetine Mesylate out of the reach of children and away from pets.

General information:

• If you have any questions about Paroxetine Mesylate, please talk with your doctor, pharmacist, or other health care provider.


• Paroxetine Mesylate is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is summary only. It does not contain all information about Paroxetine Mesylate. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Paroxetine Mesylate resources

• Paroxetine Mesylate Side Effects (in more detail)
• Paroxetine Mesylate Dosage
• Paroxetine Mesylate Use in Pregnancy & Breastfeeding
• Drug Images
• Paroxetine Mesylate Drug Interactions
• Paroxetine Mesylate Support Group
• 242 Reviews for Paroxetine Mesylate - Add your own review/rating

• Paroxetine Prescribing Information (FDA)


• Paroxetine Professional Patient Advice (Wolters Kluwer)


• Paroxetine Hydrochloride Monograph (AHFS DI)


• Paxil Prescribing Information (FDA)


• Paxil Consumer Overview


• Paxil CR Prescribing Information (FDA)


• Pexeva Prescribing Information (FDA)


• paroxetine Advanced Consumer (Micromedex) - Includes Dosage Information

Compare Paroxetine Mesylate with other medications

• Anxiety
• Anxiety and Stress
• Body Dysmorphic Disorder
• Depression
• Dysautonomia
• Dysthymia
• Generalized Anxiety Disorder
• Hot Flashes
• Obsessive Compulsive Disorder
• Panic Disorder
• Post Traumatic Stress Disorder
• Postpartum Depression
• Premenstrual Dysphoric Disorder
• Social Anxiety Disorder
• Trichotillomania
• Vulvodynia

Risperidona Kern Pharma

Risperidona Kern Pharma may be available in the countries listed below.

Ingredient matches for Risperidona Kern Pharma

Risperidone

Risperidone is reported as an ingredient of Risperidona Kern Pharma in the following countries:

• Spain

International Drug Name Search

Rispex

Rispex may be available in the countries listed below.

Ingredient matches for Rispex

Risperidone

Risperidone is reported as an ingredient of Rispex in the following countries:

• Argentina

International Drug Name Search

Ritecef-T

Ritecef-T may be available in the countries listed below.

Ingredient matches for Ritecef-T

Ceftriaxone

Ceftriaxone is reported as an ingredient of Ritecef-T in the following countries:

• India

Tazobactam

Tazobactam is reported as an ingredient of Ritecef-T in the following countries:

• India

International Drug Name Search

Rad

Rad may be available in the countries listed below.

Ingredient matches for Rad

Flupentixol

Flupentixol is reported as an ingredient of Rad in the following countries:

• Bangladesh

Melitracen

Melitracen hydrochloride (a derivative of Melitracen) is reported as an ingredient of Rad in the following countries:

• Bangladesh

International Drug Name Search

Neutase

Neutase may be available in the countries listed below.

Ingredient matches for Neutase

Lysozyme

Lysozyme hydrochloride (a derivative of Lysozyme) is reported as an ingredient of Neutase in the following countries:

• Japan

International Drug Name Search

Risperidona Dermogen

Risperidona Dermogen may be available in the countries listed below.

Ingredient matches for Risperidona Dermogen

Risperidone

Risperidone is reported as an ingredient of Risperidona Dermogen in the following countries:

• Spain

International Drug Name Search

Terry White Chemists Sertraline

Terry White Chemists Sertraline may be available in the countries listed below.

Ingredient matches for Terry White Chemists Sertraline

Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Terry White Chemists Sertraline in the following countries:

• Australia

International Drug Name Search

Ratacand Plus Paranova

Ratacand Plus Paranova may be available in the countries listed below.

Ingredient matches for Ratacand Plus Paranova

Candesartan

Candesartan cilexetil (a derivative of Candesartan) is reported as an ingredient of Ratacand Plus Paranova in the following countries:

• Denmark

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Ratacand Plus Paranova in the following countries:

• Denmark

International Drug Name Search

Ampicilina LCH

Ampicilina LCH may be available in the countries listed below.

Ingredient matches for Ampicilina LCH

Ampicillin

Ampicillin is reported as an ingredient of Ampicilina LCH in the following countries:

• Chile


• Peru

International Drug Name Search

Reactine

Reactine may be available in the countries listed below.

Ingredient matches for Reactine

Cetirizine

Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Reactine in the following countries:

• Belgium


• Canada


• Czech Republic


• Germany


• Luxembourg


• Mexico


• Netherlands


• Norway


• Poland


• Slovakia


• Spain

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Reactine in the following countries:

• Belgium


• Canada


• Germany

International Drug Name Search

Dazolin

Dazolin may be available in the countries listed below.

Ingredient matches for Dazolin

Donepezil

Donepezil hydrochloride (a derivative of Donepezil) is reported as an ingredient of Dazolin in the following countries:

• Chile

Naphazoline

Naphazoline hydrochloride (a derivative of Naphazoline) is reported as an ingredient of Dazolin in the following countries:

• Argentina

International Drug Name Search

Rexalgan

Rexalgan may be available in the countries listed below.

Ingredient matches for Rexalgan

Tenoxicam

Tenoxicam is reported as an ingredient of Rexalgan in the following countries:

• Italy

International Drug Name Search

Nitrocontin

Nitrocontin may be available in the countries listed below.

Ingredient matches for Nitrocontin

Nitroglycerin

Nitroglycerin is reported as an ingredient of Nitrocontin in the following countries:

• Bangladesh


• India


• Sri Lanka

International Drug Name Search

Rubex

Ingredient matches for Rubex

Ascorbic Acid

Ascorbic Acid is reported as an ingredient of Rubex in the following countries:

• Ireland

Doxorubicin

Doxorubicin hydrochloride (a derivative of Doxorubicin) is reported as an ingredient of Rubex in the following countries:

• United States

International Drug Name Search

RAN-Fentanyl

RAN-Fentanyl may be available in the countries listed below.

Ingredient matches for RAN-Fentanyl

Fentanyl

Fentanyl is reported as an ingredient of RAN-Fentanyl in the following countries:

• Canada

International Drug Name Search

Risperidona Temperbex

Risperidona Temperbex may be available in the countries listed below.

Ingredient matches for Risperidona Temperbex

Risperidone

Risperidone is reported as an ingredient of Risperidona Temperbex in the following countries:

• Spain

International Drug Name Search

Radistmin L

Radistmin L may be available in the countries listed below.

Ingredient matches for Radistmin L

Nicardipine

Nicardipine hydrochloride (a derivative of Nicardipine) is reported as an ingredient of Radistmin L in the following countries:

• Japan

International Drug Name Search

Oxytocin V

Oxytocin V may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Oxytocin V

Oxytocin

Oxytocin is reported as an ingredient of Oxytocin V in the following countries:

• New Zealand

International Drug Name Search

Lopinavir

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

J05AE06

CAS registry number (Chemical Abstracts Service)

0192725-17-0

Chemical Formula

C37-H48-N4-O5

Molecular Weight

628

Therapeutic Category

Antiviral agent, HIV protease inhibitor

Chemical Names

(alphaS)-Tetrahydro-N-((alphaS)-alpha-{(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-dimethylphenoxy)acetamido]butyl}phenethyl)-alpha-isopropyl-2-oxopyrimidin-1(2H)-acetamid (IUPAC)

(alphaS)-Tetrahydro-N-[(alphaS)-alpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[2-(2,6-xylyloxy)acetamido]butyl]phenethyl]-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide (WHO)

1(2H)-Pyrimidineacetamide, N-((1S,3S,4S)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-,(alphaS)-

Foreign Names

• Lopinavirum (Latin)
• Lopinavir (German)
• Lopinavir (French)
• Lopinavir (Spanish)

Generic Names

• Lopinavir (OS: USAN, BAN)
• A 157378.0 (IS: Abbott)
• ABT 378 (IS: Abbott)

Brand Names

• Aluvia (Lopinavir and Ritonavir)
  Abbott, South Africa



• Kaletra (Lopinavir and Ritonavir)
  Abbott, United Arab Emirates; Abbott, Antigua & Barbuda; Abbott, Netherlands Antilles; Abbott, Australia; Abbott, Aruba; Abbott, Bosnia & Herzegowina; Abbott, Barbados; Abbott, Belgium; Abbott, Bahrain; Abbott, Bermuda; Abbott, Bahamas; Abbott, Canada; Abbott, Switzerland; Abbott, Chile; Abbott, Colombia; Abbott, Costa Rica; Abbott, Czech Republic; Abbott, Germany; Abbott, Denmark; Abbott, Ecuador; Abbott, Egypt; Abbott, Spain; Abbott, Finland; Abbott, France; Abbott, United Kingdom; Abbott, Grenada; Abbott, Georgia; Abbott, Greece; Abbott, Guatemala; Abbott, Hong Kong; Abbott, Honduras; Abbott, Croatia (Hrvatska); Abbott, Haiti; Abbott, Hungary; Abbott, Israel; Abbott, Iraq; Abbott, Iran; Abbott, Iceland; Abbott, Italy; Abbott, Jamaica; Abbott, Jordan; Abbott, Japan; Abbott, Kuwait; Abbott, Cayman Islands; Abbott, Lebanon; Abbott, Saint Lucia; Abbott, Luxembourg; Abbott, Malaysia; Abbott, Netherlands; Abbott, Norway; Abbott, New Zealand; Abbott, Panama; Abbott, Peru; Abbott, Poland; Abbott, Portugal; Abbott, Qatar; Abbott, Serbia; Abbott, Russian Federation; Abbott, Saudi Arabia; Abbott, Sweden; Abbott, Singapore; Abbott, Slovenia; Abbott, Slovakia; Abbott, Suriname; Abbott, El Salvador; Abbott, Syria; Abbott, Turks & Caicos Islands; Abbott, Thailand; Abbott, Tunisia; Abbott, Turkey; Abbott, Trinidad & Tobago; Abbott, Taiwan; Abbott, United States; Abbott, Saint Vincent & The Grenadines; Abbott, Venezuela; Abbott, Virgin Islands (British); Abbott, Yemen; Abbott, South Africa; Abbott Laboratories, Austria; Cardinal Health, Oman



• Lopivir Plus (Lopinavir and Ritonavir)
  Grey Inversiones, Peru

International Drug Name Search

Glossary

BAN	British Approved Name
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Tizime

Tizime may be available in the countries listed below.

Ingredient matches for Tizime

Ceftazidime

Ceftazidime is reported as an ingredient of Tizime in the following countries:

• Myanmar

International Drug Name Search

Fleelaxat

Fleelaxat may be available in the countries listed below.

Ingredient matches for Fleelaxat

Sodium Phosphate

Sodium Phosphate Dibasic (a derivative of Sodium Phosphate) is reported as an ingredient of Fleelaxat in the following countries:

• Greece

International Drug Name Search

Radiopaque

Radiopaque may be available in the countries listed below.

Ingredient matches for Radiopaque

Iohexol

Iohexol is reported as an ingredient of Radiopaque in the following countries:

• India

International Drug Name Search

Rinialer

Rinialer may be available in the countries listed below.

Ingredient matches for Rinialer

Rupatadine

Rupatadine fumarate (a derivative of Rupatadine) is reported as an ingredient of Rinialer in the following countries:

• Malta


• Portugal


• Spain

International Drug Name Search

Redaflam

Redaflam may be available in the countries listed below.

Ingredient matches for Redaflam

Nimesulide

Nimesulide is reported as an ingredient of Redaflam in the following countries:

• Mexico

International Drug Name Search

Cimetidine Merck

Cimetidine Merck may be available in the countries listed below.

Ingredient matches for Cimetidine Merck

Cimetidine

Cimetidine is reported as an ingredient of Cimetidine Merck in the following countries:

• Netherlands

International Drug Name Search

Symbicort Aerosol

Pronunciation: bue-DES-oh-nide/for-MOE-ter-ol
Generic Name: Budesonide/Formoterol
Brand Name: Symbicort

Long-acting beta-agonists such as one of the active ingredients in Symbicort Aerosol (formoterol) have been rarely associated with an increased risk of asthma-related death. They may also increase the risk of asthma-related hospitalization in CHILDREN and TEENAGERS. Symbicort Aerosol should only be used to treat asthma patients who are not controlled by using another long-term asthma-control medicine. Symbicort Aerosol should not be used in patients whose asthma is well controlled by inhaled corticosteroids.

Symbicort Aerosol is used for:

Treating asthma in certain patients. It may be used for long-term treatment of chronic obstructive pulmonary disease (COPD). It may also be used for other conditions as determined by your doctor.

Symbicort Aerosol is a corticosteroid and a long-acting beta-agonist bronchodilator combination. It works by reducing inflammation and widening the airways in the lungs, which helps you breathe more easily.

Do NOT use Symbicort Aerosol if:

• you are allergic to any ingredient in Symbicort Aerosol


• you are using another medicine that has a long-acting beta-agonist (eg, salmeterol) in it


• you are having an asthma attack or severe breathing problems (eg, sudden, severe onset or worsening of asthma or COPD symptoms, such as wheezing, cough, chest tightness, shortness of breath)


• you are taking mifepristone


• you have asthma that is already well controlled with the use of a long-term asthma-control medicine (eg, inhaled corticosteroid)

Contact your doctor or health care provider right away if any of these apply to you.

Before using Symbicort Aerosol:

Some medical conditions may interact with Symbicort Aerosol. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of diabetes, heart problems (eg, fast or irregular heartbeat, heart blood vessel problems), high blood pressure, low blood potassium levels, seizures, tuberculosis, a weakened immune system, liver problems, or thyroid problems


• if you have weakened bones (eg, osteoporosis), a family history of weakened bones, or have other risk factors of weak bones (eg, smoking, poor nutrition)


• if you have a history of eye problems (eg, glaucoma, cataracts, increased eye pressure)


• if you have a fungal, bacterial, or parasitic infection; a viral infection (eg, chickenpox, measles); herpes infection of the eye; or a lung infection (eg, pneumonia)


• if you have recently been to an emergency room for asthma, have a history of frequent hospitalizations for asthma, or have ever had a life-threatening asthma attack


• if you have had an unusual reaction to a sympathomimetic medicine (eg, albuterol, pseudoephedrine), such as fast or irregular heartbeat, overexcitement, or severe trouble sleeping


• if you are taking a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) or a tricyclic antidepressant (eg, amitriptyline), or if you have taken either of these medicines within the last 14 days

Some MEDICINES MAY INTERACT with Symbicort Aerosol. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Beta-agonists (eg, albuterol), corticosteroids (eg, prednisone), diuretics (eg, furosemide, hydrochlorothiazide), or xanthines (eg, theophylline) because the risk of low blood potassium or irregular heartbeat may be increased


• Ritodrine because the risk of maternal lung edema may be increased


• Catechol-o-methyltransferase (COMT) inhibitors (eg, entacapone), clarithromycin, HIV protease inhibitors (eg, atazanavir, ritonavir), itraconazole, ketoconazole, long-acting beta-agonists (eg, salmeterol), MAOIs (eg, phenelzine), nefazodone, telithromycin, or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Symbicort Aerosol's side effects


• Barbiturates (eg, phenobarbital), beta-blockers (eg, propranolol), carbamazepine, hydantoins (eg, phenytoin), oral contraceptives, or rifampin because they may decrease Symbicort Aerosol's effectiveness or worsen your condition


• Mifepristone because the risk of its side effects may be increased by Symbicort Aerosol

This may not be a complete list of all interactions that may occur. Ask your health care provider if Symbicort Aerosol may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Symbicort Aerosol:

Use Symbicort Aerosol as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Symbicort Aerosol comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Symbicort Aerosol refilled.


• Store Symbicort Aerosol in the foil package until right before use.


• You will need to prime the inhaler before using it for the first time, any time it has not been used for more than 7 days, or if it has been dropped. To prime the inhaler, shake it for 5 seconds, then release a test spray into the air away from your face. Shake well again for 5 seconds and release a second test spray into the air.


• To use Symbicort Aerosol, remove the inhaler from the foil pouch. Write the date that you open the foil pouch on the dose tracker card that comes with Symbicort Aerosol.


• Be sure that the canister is properly placed in the inhaler unit. Shake well. Remove the mouthpiece cover. Check the mouthpiece for foreign objects. Breathe out slowly and completely. Place the mouthpiece between your lips and try to rest your tongue flat, unless your doctor has told you otherwise. Your doctor may have told you to hold the inhaler 1 or 2 inches (2 or 3 centimeters) away from the open mouth or to use a special spacing device. As you start to take a slow, deep breath, press the canister and mouthpiece together at exactly the same time. This will release a dose of Symbicort Aerosol. Continue breathing in slowly and deeply and hold for as long as comfortable, then breathe out slowly through pursed lips or your nose. If more than 1 inhalation is to be used, wait a few minutes and repeat the above steps. Keep the spray away from your eyes. Close the mouthpiece cover after each use.


• Wipe the mouthpiece clean with a dry cloth at least once a week.


• Rinse your mouth with water after you finish using the medicine (do not swallow). This will help remove excess medicine and decrease your risk of developing an oral fungal infection.


• Use the enclosed dose tracker card to keep track of the number of puffs you have used. Throw the inhaler away after you have used the labeled number of puffs or after it has been removed from the foil pouch for longer than 3 months, even if the container does not feel empty.


• Use the new inhaler that comes with each refill. Do not reuse an old inhaler. Do not use Symbicort Aerosol with a different kind of inhaler.


• Never wash the mouthpiece or any other part of the inhaler with water. Keep it dry and always store in a dry place. Do NOT try to take the inhaler apart.


• Continue to use Symbicort Aerosol even if you feel well. Do not miss any doses.


• If you miss a dose of Symbicort Aerosol, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Symbicort Aerosol.

Important safety information:

• Symbicort Aerosol may cause dizziness. This effect may be worse if you use it with alcohol or certain medicines. Use Symbicort Aerosol with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Some patients may have trouble using Symbicort Aerosol correctly. Some may also get mouth sores or a bad taste in the mouth after using it. If you have any of these problems, ask your health care provider if a spacing device may help.


• The risk of serious heart problems (eg, irregular heartbeat) may be greater if you use Symbicort Aerosol in high doses. Do NOT use more than the recommended dose or use for longer than prescribed without checking with your doctor.


• Symbicort Aerosol should be used to treat asthma only if your asthma is not well controlled while you are using a certain long-term asthma-control medicine (eg, inhaled corticosteroid) or if you have severe asthma. Contact your doctor if you have questions about this information.


• Use caution if you switch from an oral steroid (eg, prednisone) to Symbicort Aerosol. It may take several months for your body to make enough natural steroids to handle events that cause physical stress. Such events may include injury, surgery, infection, loss of blood electrolytes, or a sudden asthma attack. These may be severe and sometimes fatal. Contact your doctor right away if any of these events occur. You may need to take an oral steroid (eg, prednisone) again. Carry a card at all times that says you may need an oral steroid (eg, prednisone) if any of these events occur.


• Symbicort Aerosol may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.


• If you have not had chickenpox, shingles, or measles, avoid contact with anyone who does. Tell your doctor right away if you are exposed to anyone who has these infections.


• Do not receive a live vaccine (eg, measles, mumps) while you are taking Symbicort Aerosol. Talk with your doctor before you receive any vaccine.


• Symbicort Aerosol will not stop an asthma attack once it has already started. Be sure to carry a short-acting bronchodilator inhaler (eg, albuterol) with you at all times to treat any breathing problems that may occur between doses of Symbicort Aerosol (eg, severe or sudden onset of wheezing or shortness of breath). If you have any questions about which medicines stop asthma attacks, check with your doctor or pharmacist.


• If you have been regularly using a short-acting bronchodilator inhaler, talk with your doctor about how to use it with Symbicort Aerosol. Short-acting bronchodilators are normally only used with Symbicort Aerosol to treat breathing problems that may occur between doses.


• If your symptoms do not get better within 1 week of starting Symbicort Aerosol or if they get worse, contact your doctor right away.


• Tell your doctor at once if you notice that your short-acting bronchodilator inhaler does not work as well, if you need to use it often (eg, 4 or more times a day for more than 2 days in a row, more than 1 canister in 8 weeks), or if you have a decrease in your peak flow meter results.


• Contact your doctor or seek medical care right away if you have breathing problems that worsen quickly, or if you use your short-acting bronchodilator and do not get relief.


• Talk with your doctor or pharmacist about all of your asthma medicines and how to use them. Your doctor may make changes to your asthma-control medicines once your asthma is well controlled. Do not start, stop, or change the dose of any asthma medicine unless your doctor tells you to.


• The medicine may sometimes cause breathing problems right after you use a dose. If this happens, use your short-acting bronchodilator. Contact your doctor or seek other medical care at once.


• Lab tests, including lung function, bone density, blood pressure, and eye exams, may be performed while you use Symbicort Aerosol. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Symbicort Aerosol with caution in the ELDERLY; they may be more sensitive to its effects, especially weakened bones.


• Corticosteroids may affect the growth rate in CHILDREN and teenagers in some cases. They may need regular growth checks while they use Symbicort Aerosol.


• Symbicort Aerosol should be used with extreme caution in CHILDREN younger than 12 years old; safety and effectiveness in these children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Symbicort Aerosol while you are pregnant. Symbicort Aerosol is found in breast milk. Do not breast-feed while taking Symbicort Aerosol.

Possible side effects of Symbicort Aerosol:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Back pain; dizziness; dry mouth; headache; nausea; nervousness; stomach pain or upset; stuffy nose; throat irritation; tiredness; tremor; trouble sleeping; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, tongue, or throat; unusual hoarseness); bone pain; chest pain; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; increased mucus production or change in color of mucus; new or worsening asthma or COPD symptoms (eg, coughing, increased chest tightness, shortness of breath, wheezing); seizures; severe or persistent dizziness, headache, nervousness, or tremor; severe or persistent muscle pain or cramps; symptoms of high blood sugar (eg, increased thirst, urination, or hunger; unusual weakness or drowsiness; confusion); tingling or numbness of the arms or legs; trouble speaking; vision changes; white patches in your mouth or throat.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Symbicort side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include chest pain; fast or irregular heartbeat; fatigue; increased thirst or urination; muscle pain or cramps; seizures; severe or persistent dizziness, headache, nausea, nervousness, or tremors; severe or persistent symptoms of high blood sugar (eg, increased thirst, hunger, or urination; drowsiness; flushing of the skin; confusion; fruit-like breath odor); trouble sleeping; vomiting.

Proper storage of Symbicort Aerosol:

Store Symbicort Aerosol at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and direct sunlight. Do not store in the bathroom. Do not puncture, break, or burn the canister, even if it appears to be empty. Store Symbicort Aerosol with the mouthpiece down. Keep Symbicort Aerosol out of the reach of children and away from pets.

General information:

• If you have any questions about Symbicort Aerosol, please talk with your doctor, pharmacist, or other health care provider.


• Symbicort Aerosol is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Symbicort Aerosol. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Symbicort resources

• Symbicort Side Effects (in more detail)
• Symbicort Use in Pregnancy & Breastfeeding
• Symbicort Drug Interactions
• Symbicort Support Group
• 31 Reviews for Symbicort - Add your own review/rating

Compare Symbicort with other medications

• Asthma, Maintenance
• COPD
• COPD, Maintenance

Ebixa 10 mg Film-Coated Tablets

Ebixa 10 mg film-coated tablets

Memantine hydrochloride

Read all of this leaflet carefully before you start taking this medicine

• Keep this leaflet. You may need to read it again.


• If you have any further questions, ask your doctor or pharmacist.


• This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.


• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet

1. What Ebixa is and what it is used for

2. Before you take Ebixa

3. How to take Ebixa

4. Possible side effects

5. How to store Ebixa

6. Further information

What Ebixa Is And What It Is Used For

How does Ebixa work

Ebixa belongs to a group of medicines known as anti-dementia medicines.

Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Ebixa belongs to a group of medicines called NMDA-receptor antagonists. Ebixa acts on these NMDA-receptors improving the transmission of nerve signals and the memory.

What is Ebixa used for

Ebixa is used for the treatment of patients with moderate to severe Alzheimer’s disease.

Before You Take Ebixa

Do not take Ebixa

• if you are allergic (hypersensitive) to memantine hydrochloride or any of the other ingredients of Ebixa film-coated tablets (see section 6).

Take special care with Ebixa

• if you have a history of epileptic seizures


• if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an uncontrolled hypertension (high blood pressure).

In these situations the treatment should be carefully supervised, and the clinical benefit of Ebixa reassessed by your doctor on a regular basis.

If you suffer from renal impairment (kidney problems), your doctor should closely monitor your kidney function and if necessary adapt the memantine doses accordingly.

The use of medicinal products called amantadine (for the treatment of Parkinson´s disease), ketamine (a substance generally used as an anaesthetic), dextromethorphan (generally used to treat cough) and other NMDA-antagonists at the same time should be avoided.

Ebixa is not recommended for children and adolescents under the age of 18 years.

Using other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

In particular, Ebixa may change the effects of the following medicines and their dose may need to be adjusted by your doctor:

amantadine, ketamine, dextromethorphan

dantrolene, baclofen

cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine

hydrochlorothiazide (or any combination with hydrochlorothiazide)

anticholinergics (substances generally used to treat movement disorders or intestinal cramps)

anticonvulsants (substances used to prevent and relieve seizures)

barbiturates (substances generally used to induce sleep)

dopaminergic agonists ( substances such as L-dopa, bromocriptine)

neuroleptics (substances used in the treatment of mental disorders)

oral anticoagulants

If you go into hospital, let your doctor know that you are taking Ebixa.

Taking Ebixa with food and drink

You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.

Pregnancy and breast-feeding

Ask your doctor or pharmacist for advice before taking any medicine.

Tell your doctor if you are pregnant or planning to become pregnant. The use of memantine in pregnant women is not recommended.

Women taking Ebixa should not breast-feed.

Driving and using machines

Your doctor will tell you whether your illness allows you to drive and to use machines safely.

Also, Ebixa may change your reactivity, making driving or operating machinery inappropriate.

Important information about some of the ingredients of Ebixa

This medicinal product contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Your doctor will advise you.

How To Take Ebixa

Always take Ebixa exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

Dosage

The recommended dose of Ebixa for adults and elderly patients is 20 mg once a day. In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme:

The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is increased to one tablet once a day (1x 10 mg) in the second week and to 1 and a half tablet once a day in the third week. From the fourth week on, the usual dose is 2 tablets once a day (1x 20 mg).

Dosage in patients with impaired kidney function

If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.

Administration

Ebixa should be administered orally once a day. To benefit from your medicine you should take it regularly every day at the same time of the day. The tablets should be swallowed with some water. The tablets can be taken with or without food.

Duration of treatment

Continue to take Ebixa as long as it is of benefit to you. Your doctor should assess your treatment on a regular basis.

If you take more Ebixa than you should

• In general, taking too much Ebixa should not result in any harm to you. You may experience increased symptoms as described in section 4. “Possible side effects“.


• If you take a large overdose of Ebixa, contact your doctor or get medical advice, as you may need medical attention.

If you forget to take Ebixa

• If you find you have forgotten to take your dose of Ebixa, wait and take your next dose at the usual time.


• Do not take a double dose to make up for a forgotten dose.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Possible Side Effects

Like all medicines, Ebixa can cause side effects, although not everybody gets them.

In general, the observed side effects are mild to moderate.

Common (affects 1 to 10 users in 100):

• Headache, sleepiness, constipation, dizziness, shortness of breath, high blood pressure and drug hypersensitivity.

Uncommon (affects 1 to 10 users in 1,000):

• Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)

Very Rare (affects less than 1 user in 10,000):

• Seizures

Not known (frequency cannot be estimated from the available data):

• Inflammation of the pancreas and psychotic reactions

Alzheimer's disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with Ebixa.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How To Store Ebixa

Keep out of the reach and sight of children.

Do not use Ebixa after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Further Information

What Ebixa contains

The active substance is memantine hydrochloride. Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.

The other ingredients are lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, talc and magnesium stearate, all in the tablet core; and methacrylic acid - ethyl acrylate copolymer (1:1), sodium lauryl sulphate, polysorbate 80, talc, triacetin and simethicone emulsion, all in the tablet coating.

What Ebixa looks like and contents of the pack

Ebixa film-coated tablets are presented as white to off-white, centrally tapered oblong biconvex, film-coated tablets with a single breakline on both sides.

Ebixa film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 49 x 1 tablets, 50 tablets, 56 tablets, 56 x 1 tablets, 70 tablets, 84 tablets, 98 tablets, 98 x 1 tablets, 100 tablets, 100 x 1 tablets, 112 tablets, 980 (10 x 98) tablets or 1000 (20 x 50) tablets. The pack sizes 49 x 1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in unit dose blister.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

H. Lundbeck A/S

Ottiliavej 9

DK-2500 Valby

Denmark

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.

United Kingdom

Lundbeck Limited

Lundbeck House

Caldecotte Lake Business Park

Caldecotte

Milton Keynes

MK7 8LG

UK

Tel:+44 1908 64 9966

This leaflet was last approved in 06/2010

Detailed information on this product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu